Imexpharm opens new representative office in Ho Chi Minh City

Brand recognition enhancements

Imexpharm Pharmaceutical JSC has recently opened a representative office in Ho Chi Minh City, signifying an important growth milestone and increasing its brand recognition in major cities to serve and care for customers, partners, and investors.

Located on the 24^th floor of Flemington Tower at 184 Le Dai Hanh street in District 11, the representative office boasts a trendy and luxurious open modern space. It is equipped with modern IT systems and work rooms allowing employees to interact better and create a dynamic and cohesive working environment.

Imexpharm's Board of Directors hosted a ceremony to officially open the new office

Tran Thi Dao, general director of Imexpharm, said, "As a long-term partner with a history of attachment and development over the past 45 years in the Mekong Delta’s Dong Thap province, Imexpharm is proud to have become a leading pharmaceutical manufacturer in Vietnam. With a strategy of developing and expanding its network, Imexpharm officially opened the Ho Chi Minh City office to increase its brand recognition in major cities and to better serve customers, partners, and investors."

“The office opening is an important milestone marking our transition to a new growth cycle after a period of in-depth investment in modern production technologies,” Dao said. “Despite the ongoing challenges, we are steadfast in our belief about the steady growth of Vietnam’s economy. This is a driving force helping us believe more in the sustainable development journey that the company has outlined."

Tran Thi Dao, general director of Imexpharm, delivered a speech during the inauguration ceremony of the company's new representative office in Ho Chi Minh City

Imexpharm’s new Ho Chi Minh City office is expected to foster an environment that encourages creativity and the exchange of ideas between employees, while strengthening relationships with external partners and businesses to promote the company’s growth momentum. In 2023, Imexpharm maintained double-digit growth for the year, with total gross revenue reaching VND2.11 trillion ($86.34 million) for approximately 26 per cent growth compared to the overall market average of 8 per cent.

New growth cycle awaits

Imexpharm is ranked Number 1 in antibiotics in Vietnam. It currently owns four factory clusters, including three EU-GMP clusters with eleven production lines that meet EU-GMP standards. This gives Imexpharm the largest such cluster and largest EU-GMP chain. Moreover, Imexpharm registered eleven more EU MAs (European Product Registration Numbers) for six products in 2023, including Ampicillin / Sulbactam, which are difficult to produce and distribute. This brings the total number of EU MAs to 27 for eleven products.

Regarding the 2024 plan, Imexpharm will continue to invest in and implement initiatives to boost the productivity of existing lines and factories. It is also researching and evaluating the feasibility of a number of investment projects in new factories and lines to meet growing domestic and foreign needs.

“Imexpharm will expand its network to the northern region to help provide high-quality healthcare products at reasonable cost to hospitals, pharmacies, and people,” Dao said. “Not only meeting domestic healthcare demand, Imexpharm has also set a goal of setting foot in new markets of potential. At the beginning of 2024, we successfully exported our first shipment of antibiotics to Mongolia by air.”

Imexpharm has built a wide network throughout Vietnam from the north to the south, with 20 sales branches. There are two branch offices in Ho Chi Minh City and two warehouses in the southern city and Dong Thap province.

Operating a modern representative office affirms the management philosophy of Imexpharm, that “people are the source of all success”. This has been the driving force helping the company rise from a small factory in Dong Thap to continuous achievements since its model transformation began in 2001.

Imexpharm currently has a team of human resources of more than a thousand people. Its stable growth has been attributed to an excellent management system, and this has been recognised by numerous awards, such as a top 50 Vietnamese enterprise for attractive recruitment, top 5 excellent Board of Directors, and a top 5 company with the best working environment in Vietnam in the pharmaceutical industry, especially for medium-sized enterprises producing medical equipment and supplying healthcare services.

The general director believes Imexpharm's achievements are the result of a long process of upgrading its working environment by harmoniously combining cultural identity and international management standards with people as the core element. With the expansion of sales branches around the country, Imexpharm is also actively promoting personnel training and community activities.

Notably, over the years, it has been recognised for many initiatives to encourage health check-ups and provide medicine for people living in difficult circumstances nationwide. This emphasises its dedication to having a positive impact on the modern healthcare industry as well as Vietnamese society.

Imexpharm honoured as top 5 company with best working environment in Vietnam Imexpharm Pharmaceutical JSC has been named in the top 5 companies with the best working environment in Vietnam for pharmaceuticals, medical devices, and healthcare companies in the medium-sized enterprise category.

Imexpharm clinches top honours in corporate annual reporting Imexpharm, outstripping its 2023 financial targets, underscores its ascent with top honours in corporate governance, affirming its stature in Vietnam's pharmaceutical sector.

Domestic pharmaceutical products anticipate 2024 boost 2023 witnessed many fluctuations in the economy, with various industrial fields witnessing negative growth, but the pharmaceutical industry remains growing thanks to the breakthroughs of leading pharmaceutical companies.